SCHEMBL25596152

SCHEMBL25596152

CCOc1ccc(C(=O)Oc2c(F)c(F)c(F)c(F)c2F)cc1N1CCC(=O)NC1=O

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 4/20 0.41
CRBN Q96SW2 4/20 0.41
CYP2C19 P33261 3/20 0.40
CYP2C9 P11712 2/20 0.40
SRD5A1 P18405 2/20 0.40
SRD5A2 P31213 2/20 0.40
POLB P06746 1/20 0.39
CTDSP1 Q9GZU7 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
CYP1A2 P05177 2/20 0.37
MAPT P10636 2/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
HTT P42858 1/20 0.37
KMT2A Q03164 3/20 0.37
MEN1 O00255 1/20 0.37
CYP3A4 P08684 1/20 0.37
LMNA P02545 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29721010 0.89 DDB1 (0.39) DDB1CRBNSRD5A1SRD5A2POLB
SCHEMBL21408889 0.89 DDB1 (0.39) DDB1CRBNSRD5A1SRD5A2POLB
SCHEMBL31524286 0.87 DDB1 (0.40) DDB1CRBNSRD5A1SRD5A2
SCHEMBL25596158 0.86 DDB1 (0.37) DDB1CRBNSRD5A1SRD5A2
SCHEMBL30014315 0.86 DDB1 (0.37) DDB1CRBNSRD5A1SRD5A2
SCHEMBL25256759 0.85 CRBN (0.41) DDB1CRBNSRD5A1SRD5A2
SCHEMBL29892316 0.85 CRBN (0.41) DDB1CRBNSRD5A1SRD5A2
SCHEMBL30267074 0.84 DDB1 (0.49) DDB1CRBNCYP2C9SRD5A1SRD5A2
SCHEMBL29318952 0.84 DDB1 (0.49) DDB1CRBNCYP2C9SRD5A1SRD5A2
SCHEMBL21408861 0.84 TSHR (0.48) DDB1CRBNCYP2C19CYP2C9POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368194-A1 IRAK4 DEGRADATION AGENT, AND PREPARATION METHOD THEREFOR AND USE THEREOF LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) 2024-11-07 US disclosed
WO-2024146502-A1 WEE1 DEGRADING COMPOUNDS BEIJING NEOX BIOTECH LIMITED (CN) 2024-07-11 WO disclosed
US-20230234936-A1 COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) 2023-07-27 US disclosed
US-20230234936-A1 COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) 2023-07-27 US disclosed
EP-4194457-A1 COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF Shanghai Leadingtac Pharmaceutical Co., Ltd. (CN) 2023-06-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234936-A1 COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF IRAK4, IRAK2, IRAK1 DDB1 1973/4885CRBN 221/4885CYP2C19 4517/4885
US-20240368194-A1 IRAK4 DEGRADATION AGENT, AND PREPARATION METHOD THEREFOR AND USE THEREOF IRAK4, IRAK2, IRAK1 DDB1 2931/4885CRBN 545/4885CYP2C19 4555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.